INTRODUCTION
After the first successful lung transplantation (LTx) in 1983, 1 more than 10 000 LTx have been performed in the world, with approximately 1000 new cases each year in recent years. 2 Lung transplantation is established as the ultimate treatment for end-stage pulmonary diseases in developed countries, except Japan. Clinical application of LTx was delayed in Japan until the Japanese Brain Death Act (JBDA) for organ transplantation was enforced in October 1997. Major indications for LTx in Japan are quite different from those in Western countries. Six LTx from brain-dead cadaver donors (BDCDs) have been performed in Japan and LTx becomes a clinical option for end-stage lung diseases in our country. Because BDCDs are quite precious, LTx from living donors is thought to be an alternative choice for selected patients, as well as renal or liver transplantation, in Japan. The present review analyzes the current status and future trends of LTx in Japan.
CURRENT STATUS OF LTX IN JAPAN Indication for LTx and the transplant window in Japan
Clinical organ transplantation from BDCD was not accepted for a long time in Japan. After the submission of a report from the National Brain Death Investigative Committee in 1992, the JBDA for organ transplantation was enforced in October 1997. Since then, organ transplantation from BDCD has become a real clinical option in this country. Four lung transplant centers were selected in April 1998 and registration of candidates for LTx started in August 1998. 3 The indicated lung diseases for LTx in Japan are limited to chronic advanced lung disorders for which no further medical or surgical therapies are available. Japanese criteria for LTx include a limitation of recipient age. Heart-lung and bilateral transplantation are restricted to patients under 55 years of age and single LTx is restricted to patients under 60 years of age. A Council for Lung and Heart-Lung Transplantation Organized with Related Societies approved 16 pulmonary diseases and one status (Table 1) . 3 The indications for LTx include pulmonary vascular diseases, parenchyma lung diseases and diffuse pulmonary lesions due to several systemic diseases. Although survival limitation of candidates has not been clearly decided in Japan, an estimated survival of less than 2-3 years, as for candidates in Western countries, is usually accepted. 4 The transplant window means a recipient who has severe respiratory failure but does not have irreversible damage in other organ functions (Fig. 1) . The transplant window must be considered in the assessment of each patient. Early registration is strongly recommended in the US because there is expected to be a wait of more than 600 days before LTx. The 6 min walk distance is thought to be a good indicator of total cardiopulmonary function. 5 However, it is difficult to assess the condition of each candidate, with a variety of pulmonary disorders, using a common standard. Therefore, international guidelines for the selection of LTx candidates based on major indications were submitted in 1998 (Table 2) . 6 These guidelines are very useful and are also acceptable in our country.
Registration for LTx in Japan
Candidates for LTx from BDCD must be registered on the Japan Organ Transplant Network (JOTNW) waiting list. The process of registration requires two different appraisals by LTx assessment committees, which are an institutional/ regional committee and a nationwide committee (Fig. 2) . 3 In addition, the validity of LTx for each candidate must be confirmed ethically by the institutional ethics committee. Thus, in Japan, it takes 2 or 3 months for the assessment and the process of registration to be completed. During this process, informed consent is obtained from candidates and their family.
Analysis of waiting patients for LTx
From August 1998 to March 2001, 51 candidates were accepted and registered on the waiting list. Only eight patients (16%) have received lung allografts during this period and 14 patients (27%) have already died (Fig. 3) . Major causes for LTx candidates are primary pulmonary hypertension (PPH) in 23 cases (45.1%), idiopathic pulmonary fibrosis/interstitial pneumonia (IPF/IIP) in eight cases (15.7%), lymphangioleiomyomatosis (LAM) in seven cases (13.7%) and bronchiectasis (BE) in six cases (11.8%). The disease entities in Japan are quite different from those in Western countries (Fig. 4) . 2 Juvenile emphysema, cystic fibrosis and α 1 -antitrypsin-deficient emphysema are major indications in the international registry; in contrast, there are very few cases with these diseases in Japan. 7, 8 All eight patients who received LTx are alive and doing well; in contrast, the survival of the other patients who could not have LTx is limited (Fig. 5) . These prognoses for patients who do not undergo LTx vary according to primary disease. The prognosis for PPH is best, with a 2 year survival for over 80% of cases. The prognosis for IPF/IIP is worst and all candidates with IPF/IIP had died within 1 year if they could not receive LTx (Fig. 5) . 
Lung transplantation from BDCD
The first LTx from BDCD were performed at Osaka University and Tohoku University as left and right two single LTx from the same donor on March 2000. 9,10 Six LTx from BDCD have been performed in Japan (Table 3) . The types of procedure include single LTx in five cases and bilateral LTx in one case; the primary diseases are LAM in three cases, IPF/IIP in two cases and PPH in one case. All patients who have received LTx are alive and well and several recipients have already returned to an active life without oxygen therapy.
Brain dead and living donors
It is estimated that approximately 7000 brain deaths occur every year in Japan;however, only less than 10 cases a year will be available for LTx based on our experience to date. The donation may be quite limited, because the JBDA for organ transplantation requires a written will for a person to donate his/her organs, which is estimated only 10% of the population have. A donor card campaign and education about organ transplantation 4 Y MATSUMURA ET AL. are quite necessary to increase the number of donors. The lung is very susceptible to damage in the process of drain death and during management with a ventilator. Lung edema, aspiration and pneumonia disturb the utilization of lung allografts. The utilization of BDCD for LTx is generally lower than for kidney, liver and heart allografts. The average BDCD utilization for LTx is only 10-20%. 11 Utilization of lungs in the US was 13% according to the United Network for Organ Sharing (UNOS) 1998 report (http://www.unos.org; Fig. 6 ). Because organ shortages are serious in Western countries, the criteria for lung donors have been relaxed to expand donor pools. 4, [12] [13] [14] At present, the upper age limit has been extended to 65 years. Unilateral chest shadow on chest X-ray films, a small amount of purulent airway secretion and detection of bacteria from airway secretion of donors are no longer contraindications for LTx. These are called marginal donors. It was reported that number of lung donors increased 1.4-2.0-fold after utilization of marginal donors. 13, [15] [16] [17] We have attempted to use marginal donors aggressively and could use lung grafts in five of 13 BDCD (36%) ( Table 4) .
Living-donor lobar transplantation
Living-donor lobar LTx (LDLTx) was introduced as an alternative method to expand donor pools. The first LDLTx applied to an infant used one lobe in 1990. 18 Thereafter, double-lobar transplantation from two living was donors developed and applied to adult patients. [19] [20] [21] Because BDCD is not frequent in Japan, LDLTx is chosen as another option more frequently in Japan than in the US.
In Japan, after the first LDLTx at Okayama University in 1998, 22 eight LDLTx have been performed (Table 5 ). All LDLTx were double-lobar transplantation from two living donors and each donor provided a right or left lower lobe. Primary diseases of the recipients were BE in two 6 Y MATSUMURA ET AL. cases, bronchiolitis obliterans in two cases, IPF/IIP in two cases, LAM in one case and PPH in one case. All patients who received LDLTx are alive and well. Living-donor organ transplants have been mainstreams in renal and liver transplantation in Japan because of a severe donor shortage. The same trend may develop for LTx. However, the cumulative number of LDLTx is only less than hundreds in the world; at present, LDLTx is still a developing and experimental treatment for terminal respiratory disorders and the advantages and disadvantages of LDLTx should be carefully considered. 21, [23] [24] [25] [26] The benefits of LDLTx are: (i) scheduled and well-prepared operations; (ii) excellent donor assessment and condition; (iii) short graft ischemic time; and (iv) mild rejection compared with cadaver transplantation because of minor HLA mismatch between blood relatives. In contrast, the disadvantages and risks of LDLTx are: (i) surgical risks for two living donors; (ii) 10-20% loss of donor lung function; (iii) difficulty of the LDLTx operation compared with cadaver LTx; and (iv) a limit to the lung volume that can be donated. Universal guidelines for donors for LDLTx have not yet been established. 25, 26 We have restricted living donors to family members, from 19 to 60 years of age, with compatible blood types. Transplant lung volume is the most important restrictive factor. Using our criteria, the estimated volume of donor lobes must be more than 50% predicted vital capacity of the recipient.
PROSPECTS FOR LTX AND PROBLEMS TO BE

SOLVED
The beginning of LTx in Japan is more than 10 years behind the US; nevertheless, early excellent results were obtained, possibly because initial transplant centers were restricted to four well-prepared and advanced hospitals. After a successful beginning, acceptable intermediate results will be most important to establish LTx as a clinical option for end-stage lung diseases in the Japanese community. In order to achieve this, the establishment of a management system of far-distant transplant patients is essential. Prompt and precise communication between recipients, local hospitals and transplant centers can be maintained with telephone, fax and especially with the internet. Early detection and measures against chronic rejection are keys for long survival and for maintaining good allograft function. In addition, Japanese health insurance shall cover LTx and immunosuppressive drugs as early as possible. Many patients cannot be considered as candidates for economic reasons. Lung transplantation for children is also a subject to be considered, because, at present, only living related LTx is a possible transplant option for children in Japan. Utilization of BDCD under 15 years of age, split lobar transplantation from adult lung allograft and down-sizing LTx must be considered in LTx for children and infants. [27] [28] [29] Finally, expansion of the donor source is the most important and urgent problem. Clinical lung preservation longer than 8 h and clinical utilization of lung allografts from cardiac arrest donors will be acceptable goals in the near future. Both have been already established in animal experiments and clinical trials are underway. 30 Thereafter, xenotransplantation and/or artificial lungs will be appear on the horizon as the next goals to be solved in the 21st century.
